Intraarticular treatments for osteoarthritis: New perspectives

Current Drug Targets

Volumn 11, Issue 5, 2010, Pages 546-560

  Chevalier, Xavier ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cytokines; Gene therapy; Growth factors; Intra articular; Lubricin; Osteoarthritis; Stem cells; Therapy

Indexed keywords

ADALIMUMAB; ADENOVIRUS VECTOR; AUTOLOGOUS CONDITIONED SERUM; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; BOTULINUM TOXIN; COMPLEMENTARY DNA; ELASTIN; GLUCOCORTICOID; GROWTH FACTOR; HYALURONIC ACID; INTERLEUKIN 17; INTERLEUKIN 18; KALLISTATIN; LENTIVIRUS VECTOR; LEUKEMIA INHIBITORY FACTOR; LUBRICATING AGENT; LUBRICIN; MONOCLONAL ANTIBODY; ORTHOKINE; PARVOVIRUS VECTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE 3; RETINOIC ACID SENSITIVE PROTEIN; RETROVIRUS VECTOR; RIBOZYME; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTISENSE THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; KNEE OSTEOARTHRITIS; NONHUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; TARGET ORGAN; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT BEARING;

ANIMALS; ANTIRHEUMATIC AGENTS; CYTOKINES; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-1BETA; LUBRICANTS; MODELS, BIOLOGICAL; OSTEOARTHRITIS; STEM CELL TRANSPLANTATION;

EID: 77951060526     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791011866     Document Type: Review

References (131)

1. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002; 14: 573-577
2. Sarzi-Puttini P, Cimmino R, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Sem Arthritis Rheum 2005; 35: 1-10.
3. Chevalier X. Physiopathogenesis of osteoarthritis. The osteoarthritic cartilage. Presse Med 1998; 27: 81-87
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartil 2008; 16: 137-162
5. Richmond JC. Surgery for osteoarthritis of the knee. Med Clin North Am 2009; 93: 213-222
6. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartil 2008; 16 (Suppl 3): S1-3.
7. Gosset M, Berenbaum F, Levy A, et al. Mechanical stress and prostaglandin E2 synthesis in cartilage. Biorheology 2008; 45: 301-320
8. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-1267
9. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-371
10. Pelletier JP, Martel-Pelletier J, Abramson SE. Review: Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-1247
11. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis: results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartil 2005; 13: 361-367
12. Sanchez C, Deberg MA, Bellahcène A, et al. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum 2008; 58: 442-455
13. Ashraf S, Walsh DA. Angiogenesis in osteoarthritis. Curr Opin Rheumatol 2008; 20: 573-580
14. Roach HI, Aigner T, Soder S, Haag J, Welkerling H. Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. Curr Drug Targets 2007; 8: 271-282
15. D'Lima DD, Hashimoto S, Chen PC, Colwell CW jr, Lotz MK. Human chondrocyte apoptosis in response to mechanical injury. Osteoarthritis Cartil 2001; 9: 712-719 (Pubitemid 33076762)
16. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004; (427 Suppl): S27-36.
17. Lafeber FPJG, von Roy HLAM, van den Kraan PM, van den Berg WB, Biljsman WJ. TGFβ predominantly stimulates phenotypically changed chondrocytes in osteoarthritic human cartilage. J Rheumatol 1997; 24: 536-542
18. Blanco F, Ochs RL, Scharwz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide: a hypothesis for cartilage degradation. Arthritis Rheum 1994; 37(S 294): 802.
19. Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis 2006; 65: 1403-1405
20. Bertazzolo N, Punzi L, Stefani MP, et al. Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions 1994; 41: 90-92
21. Pearle AD, Scanzello CR, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartil 2007; 15: 516-523
22. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 2006; 58: 226-242
23. Brandt KD, Smith GN Jr, Simon LS. Intra-articular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 2000; 43: 1192-1203
24. Schumacher HR. Aspiration and injection Therapies for joints. Arthritis Rheum 2003; 49: 413-420
25. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; 19: CD005328.
26. Jones A, Doherty M. Intra-articular glucocorticoids and other injection therapies, in: Brandt KD., Doherty M., Lohmander LS. (Eds), Osteoarthritis, Oxford University Press, New-York 2003.
27. Ayral X. Injections in the treatment of Osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 609-626
28. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716-1723
29. Chevalier X. Up-regulation of enzymatic activity by interleukin-1 in osteoarthritis. Biomed Pharmacother 1997; 51: 58-62.
30. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol 2008; 35:2306-2312
31. Majumdar MK, Askew R, Schelling S, et al. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 2007; 56: 3670-3674
32. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005; 52: 128-135
33. Cernanec JM, Weinberg JB, Batinic-Haberle I, Guilak F, Fermor B. Influence of oxygen tension on interleukin 1-induced peroxynitrite formation and matrix turnover in articular cartilage. J Rheumatol 2007; 34: 401-407
34. Caramés B, López-Armada MJ, Cillero-Pastor B, et al. Differential effects of tumor necrosis factor-alpha and interleukin-1beta on cell death in human articular chondrocytes. Osteoarthritis Cartil 2008; 16: 715-722
35. Davies CM, Guilak F, Weinberg JB, Fermor B. Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis. Osteoarthritis Cartil 2008; 16: 624-630
36. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001; 44: 585-594
37. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2: 108-115
38. Van den Berg WB. Arguments for interleukin-1 as a target in chronic arthritis. Ann Rheum Dis 2000; 59 (Suppl 1): 81-84
39. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 2008; 58: S110-22.
40. Smeets RL, van de Loo FA, Joosten LA, et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum 2003; 48: 2949-2958
41. Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104: 11742-11747
42. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. IL-1b converting enzyme, inducible nitric oxide synthase, or stromelysin-1 accelerates the development of knee osteoarthritis in mice after surgical trans section of the medial collateral ligament and partial medial menisectomy. Arthritis Rheum 2003; 48: 3352-3363
43. Schaefer JF, Millham ML, de Crombrugghe B, Buckbinder L. FGF signaling antagonizes cytokine-mediated repression of Sox9 in SW1353 chondrosarcoma cells. Osteoarthritis Cartil 2003; 11: 233-241
44. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809.
45. Van Den Berg WB. Anti cytokine therapy in chronic arthritis. Arthritis Res Ther 2001; 3: 18-26.
46. Sachs D, Cunha FQ, Poole S, Ferreira SH. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002; 96: 89-97.
47. Wolf G, Yirmiya R, Goshen I, et al. Impairment of interleukin-1 (IL-1) signalling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain 2003; 104: 471-480
48. Morioka N, Takeda K, Kumagai K, et al. Interleukin-1beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cytosolic type IV. J Neurochem 2002; 80: 989-997
49. Chevalier X, Mugnier B, Bouvenot G. Targeted therapies for anticytokines therapies for osteoarthritis. Bull Acad Natl Med 2006; 190: 1411-1420
50. Goupille P, Mulleman D, Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther 2007; 9: 110.
51. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535-1544
52. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012-1019
53. Fernandes JC, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthrosis progression. Am J Pathol 1999; 154: 1159-1169
54. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, Mc Illbraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12-20.
55. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 antagonist and interleukin-10. J Orthop Res 2004; 22: 742-750
56. Wang HJ, Yu CL, Kishi H, Motoki K, Mao ZB, Muraguchi A. Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer. Chin Med J (Engl) 2006; 119: 1365-1373
57. Breshinan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology 2003; 42 (Suppl 2): 22-28
58. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32(7): 1317-1323
59. Chevalier X, Goupille P, Beaulieu AD, et al. Intra-Articular Injection of Anakinra (r-met-huIL-1ra) in Osteoarthritis of the Knee: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. Arthritis Rheum 2009; 61: 344-352
60. Loeuille D, Chary-Valckeneare I, Goebel G, et al. MRI evaluation of the synovial membrane after single intra-articular injection of Anakinra in 7 patients with osteoarthritis of the knee suggests antiinflammatory effect. Arthritis Rheum 2005; 52 (Suppl 9); S70: 94.
61. Richette P, François M, Vicaut E, et al. Rheumatology 2008; 35: 1650-1654
62. Cohen S, Proudman S, Kivitz A, et al. Results of a randomised controlled trial of AMG 108 (a fully monoclonal human antibody to IL1R type 1) in patients with osteoarthritis of the knee. Arthritis Rheum 2007; 56 (Suppl 9): 1684.
63. Wehling P, Moser C, Frisbie D, et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs 2007; 21: 323-332
64. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290-296
65. Yang KG, Raijmakers NJ, van Arkel ER, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartil 2008; 16: 498-505.
66. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartil 2009; 17(2): 152-160
67. Kim HA, Blanco FJ. Cell death and apoptosis in osteoarthritic cartilage. Cur Drug Targets 2007; 8: 333.
68. D'Lima D, Hermida J, Hashimoto S, Colwell C, Lotz M. Intraarticular injection of a pan caspase inhibitor or of specific inhibitor in a dog model of OA a decrease in the number of apoptotic chondrocytes (Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis. Arthritis Rheum 2006; 54 (6): 1814-1821.
69. Mahowald ML, Singh JA, Dykstra D. Long term effects of intraarticular botulinum toxin A for refractory joint pain. Neurotox Res 2006; 9: 179-188
70. Mahowald ML, Singh JA, Goelz E, Kushnaryov A, Krug HE. Intraraticular botulinum toxin type A for refractory knee pain: randomized controlled trial in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2006; 56(Suppl 9): 54: L1.
71. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008; 10: R63.
72. Black RA. TIMP3 checks inflammation. Nat Gen 2004; 36(9): 934-935
73. Black RA, Castner B, Slack J, Tocker J, Eisenman J. Injected TIMP-3 protects cartilage in a rat meniscal tear model. Osteoarthritis Cartil 2006; 14 (Suppl B): S23: A14.
74. Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 2006; 58: 243-258
75. Evans CH. Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs 2005; 19: 355-362
76. Nixon AJ, Goodrich LR, Scimeca MS, et al. Gene therapy in musculoskeletal repair. Ann N Y Acad Sci 2007; 1117: 310-327
77. Evans C, Ghivizzani SC, Robbins PD. Gene therapy for rheumatic disease: 1998-2008. Arthritis Res Ther 2009; 11: 209-216
78. Toh ML, Hong SS, van de Loo F, et al. Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)- and non-RGD-binding integrins. J Immunol 2005; 175: 7687-7698
79. Bondenson J. The role of activated synovila macrophages ein osteoarthritis. Osteoarthritis Cartil 2008; 16 (Suppl 4): S8(I-24).
80. Hsieh J, Shen PC, Shiau AL, et al. Adenovirus-Mediated Kallistatin Gene Transfer Ameliorates Disease Progression in a Rat Model of Osteoarthritis Induced by Anterior Cruciate Ligament Transection. Hum Gene Ther 2009; 20(2): 147-158
81. Ghivizzani SC, Gouze E, Gouze JN, et al. Perspectives on the use of gene therapy for chronic joint diseases. Curr Gene Ther 2008; 8(4): 273-286
82. Evans CH, Robbins PD, Ghivizzani SC, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280
83. Wehling P, Reinecke J, Baltzer AA, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther 2008. [Epub ahead of print].
84. Evans C, Ghivizzani SC, Robbins PD. Arthritis gene therapy first death. Arthritis Res Ther 2008; 10: 110.
85. Izal I, Acosta CA, Ripalda P, Zaratiegui M, Ruiz J, Forriol F. IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage. Arch Orthop Trauma Surg 2008; 128: 239-247
86. Trippel S, Cucchiarini M, Madry H, Shi S, Wang C. Gene therapy for articular cartilage repair. Proc Inst Mech Eng H 2007; 221: 451-459
87. Huber LC, Distler O, Gay RE, Gay S. Antisense strategies in degenerative joint diseases: sense or nonsense. Adv Drug Deliv 2006; 58: 285-299
88. Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 2005; 52: 1314-1318 (Pubitemid 40530142)
89. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartil 2008; 16: 174-184
90. Oliveira S, Storm G, Schiffelers RM. Targeted Delivery of siRNA. J Biomed Biotechnol 2006; 2006: 63675.
91. Shamji MF, Betre H, Kraus VB, et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local anti inflammatory therapeutic. Arthritis Rheum 2007; 56: 3650-3661 (Pubitemid 350100699)
92. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. A thermally responsive biopolymer for intra-articular drug delivery J Control Release 2006; 115: 175-182.
93. Shimizu S, Asou Y, Itoh S, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007; 56: 3358-3365 (Pubitemid 47585430)
94. Kadri A, Ea HK, Bazille C, Hannouche D, Lioté F, Cohen-Solal ME. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008; 58: 2379-2386
95. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007; 8: 283-292
96. Scharstuhl A, Glansbeek HL, van Beuningen HM, et al. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 2002; 169: 507-514 (Pubitemid 34686173)
97. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003; 48: 3442-3451
98. Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints. Lab Invest 1998; 78: 133-142
99. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduced transforming growth factor-beta signaling in cartilage of old mice: role in impaired repair capacity. Arthritis Res Ther 2005; 7: R1338-47.
100. Bakker AC, van de Loo FA, van Beuningen HM, et al. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer- dependent chondro-osteophyte formation. Osteoarthritis Cartil 2001; 9: 128-136
101. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartil 2007; 15: 237-244
102. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartil 1998; 6: 306-317
103. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14 (6): 681-685
104. Blaney-Davidson EN, Vitters El, Oliver N. et al. Transforming growth factor beta induced persistent synovila fibrosis while connectyive tissue growthfactor-induced fibrosis isq reversible / role for lysis hydroxylase. Osteoarthritis Cartil 2008; 16(Suppl 4): A 10.
105. Blaney Davidson EN, Vitters EL, van den Berg WB, van der Kraan PM. TGF beta-induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad 7. Arthritis Res Ther 2006; 8: R65.
106. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-beta injections. Osteoarthritis Cartil 2000; 8: 25-33.
107. Brown KE, Leong K, Huang CH, et al. Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 1998; 41: 2185-2195
108. Inoue A, Takahashi KA, Arai Y, et al. The therapeutic effects of basic fibroblast growth factor contained in gelatin hydrogel microspheres on experimental osteoarthritis in the rabbit knee. Arthritis Rheum 2006; 54: 264-270
109. Tscheudschilsuren G, Bosserhoff AK, Schlegel J, et al. Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA. Exp Cell Res 2006; 312: 63-72.
110. Saito S, Kondo S, Mishima S, et al. Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br 2002; 84: 1066-1069
111. Pittenger, MF, Mackay AM, Beck, SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147
112. Wakitani S, Yamamoto T. Response of the donor and recipient cells in mesenchymal cell transplantation to cartilage defect. Microsc Res Tech 2002; 58: 14-18
113. Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noël D. Multipotent mesenchymal stromal cells in articular diseases. Best Pract Res Clin Rheumatol 2008; 22: 269-284 (Pubitemid 351606945)
114. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med 2007; 1: 74-79
115. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003; 48: 3464-3474
116. Read R, Cake M, Smith T, et al. Dose dependent chondroprotective effects of allogenic STRO3+ mesenchymal precursor stem cells following direct intraarticular injection into joints of an ovine model of early osteoarthritis. Osteoarthritis Cartil 2008; 16(Suppl 4): S18: A12.
117. Black LL, Gaynor J, Gahring D, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther 2007; 8: 272-284
118. Black LL, Gaynor J, Adams C, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008; 9(3): 192-200.
119. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Cochrane Database Syst Rev Viscosupplementation for the treatment of osteoarthritis of the knee. 2006; (2): CD005321.
120. Jones AR, Gleghorn JP, Hughes CE, et al. Binding and localization of recombinant lubricin to articular cartilage surfaces. J Orthop Res 2007; 25: 283-292
121. Flannery CR, Zollner R, Corcoran C, et al. Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum 2009 26; 60: 840-847
122. Amiel D, Toyogushi T, Kobatashi K, Bowden K, Amiel ME, Healey RM. Long term effect of sodium hyaluronate (hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthritis Cartil 2003; 11: 636-643
123. Listrat V, Ayral X, Patarnello F, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan ( hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartil 1997; 5: 153-160
124. Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 2003; 57: 467-474
125. Schmidt TA, Gastelman NS, Nguyen QT, Schumacher BL, Sah RL. Boundary lubrication of articular cartilage: role of synovial fluid constituents. Arthritis Rheum 2007; 56: 882-891
126. Jay GD, Torres JR, Warman ML, Laderer MC, Breuer KS. The role of lubricin in the mechanical behaviour of synovial fluid. Proc Natl Acad Sci USA 2007; 104: 6194-6199
127. Durigova M, Roughley PJ, Mort JS. Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthritis Cartil 2008; 16: 98-104.
128. Luyten FP, Tylzanowski P, Lories RJ. Wnt signaling and osteoarthritis. Bone 2009; 44: 522-527
129. Lories RJ, Peeters J, Bakker A, et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007; 56: 4095-4103
130. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8: R187.
131. Blom AB, van Lent PL, Libregts S, et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum 2007; 56: 147-157